Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Public ClinicalTrials.gov record NCT02106832. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate if the time to first pulmonary exacerbation of bronchiectasis or its frequency can be prolonged by inhalation of ciprofloxacin for 28 days every other 28 days or for 14 days every other 14 days over 48 weeks.
Study identification
- NCT ID
- NCT02106832
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 521 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 29, 2014
- Primary completion
- Sep 12, 2016
- Completion
- Oct 18, 2016
- Last update posted
- Oct 1, 2017
2014 – 2016
United States locations
- U.S. sites
- 22
- U.S. states
- 13
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Peoria | Arizona | 85381 | — |
| Not listed | Fountain Valley | California | 90708 | — |
| Not listed | La Jolla | California | 92037 | — |
| Not listed | Long Beach | California | 90813 | — |
| Not listed | Newport Beach | California | 92663 | — |
| Not listed | San Diego | California | 92120 | — |
| Not listed | Kissimmee | Florida | 34741 | — |
| Not listed | Miami | Florida | 33126 | — |
| Not listed | Sarasota | Florida | 34239 | — |
| Not listed | Tampa | Florida | 33613 | — |
| Not listed | Decatur | Georgia | 30033 | — |
| Not listed | Skokie | Illinois | 60076 | — |
| Not listed | Olathe | Kansas | 66061 | — |
| Not listed | Rochester | Minnesota | 55905 | — |
| Not listed | Brooklyn | New York | 11229 | — |
| Not listed | Mineola | New York | 11501 | — |
| Not listed | Asheville | North Carolina | 28801 | — |
| Not listed | Portland | Oregon | 97239 | — |
| Not listed | Doylestown | Pennsylvania | 18901 | — |
| Not listed | Greenville | South Carolina | 29615 | — |
| Not listed | Edinburg | Texas | 78539 | — |
| Not listed | Tyler | Texas | 75708-3154 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 185 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02106832, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 1, 2017 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02106832 live on ClinicalTrials.gov.